Embodiments of a compact portable nuclear magnetic resonance (NMR) device are described which generally include a housing that provides a magnetic shield; an axisymmetric permanent magnet assembly in the housing and having a bore, a plurality of magnetic elements that together provide a well confined axisymmetric magnetization for generating a near-homogenous magnetic dipole field B.sub.0 directed along a longitudinal axis and providing a sample cavity for receiving a sample, and high magnetic permeability soft steel poles to improve field uniformity: a shimming assembly with coils disposed at the longitudinal axis for spatially correcting the near homogenous magnetic field B.sub.0; and a spectrometer having a control unit for measuring a metabolite in the sample by applying magnetic stimulus pulses to the sample, measuring free induction delay signals generated by an ensemble of hydrogen protons within the sample; and suppressing a water signal by using a dephasing gradient with frequency selective suppression.

Embodiments of a compact portable nuclear magnetic resonance (NMR) device are described which generally include a housing that provides a magnetic shield; an axisymmetric permanent magnet assembly in the housing and having a bore, a plurality of magnetic elements that together provide a well confined axisymmetric magnetization for generating a near-homogenous magnetic dipole field B.sub.0 directed along a longitudinal axis and providing a sample cavity for receiving a sample, and high magnetic permeability soft steel poles to improve field uniformity: a shimming assembly with coils disposed at the longitudinal axis for spatially correcting the near homogenous magnetic field B.sub.0; and a spectrometer having a control unit for measuring a metabolite in the sample by applying magnetic stimulus pulses to the sample, measuring free induction delay signals generated by an ensemble of hydrogen protons within the sample; and suppressing a water signal by using a dephasing gradient with frequency selective suppression.

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

The invention pertains to advances in real-time methods in nuclear magnetic resonance by offering a new dual-frequency dynamic nuclear polarization (DNP) method that uses a microwave beam to polarize the spins of electrons and concomitantly act as a NMR transmitter.

An MR Spectroscopy (MRS) system and approach is provided for measuring spectral information corresponding with propionic acid (PA), either alone or in combination with other measurements corresponding with other chemicals, to diagnose and/or monitor at least one of bacterial infection, such as associated with P. acnes, or conditions related thereto such as nociceptive pain associated with tissue acidity. An interfacing DDD-MRS signal processor receives output signals to produce a post-processed spectrum, with spectral regions corresponding with certain chemicals, including PA, then measured as biomarkers. A diagnostic processor derives a diagnostic value for each disc, and performs certain normalizations, based upon ratios of the spectral regions related to chemicals implicated in degenerative painful tissue pathology, such as PA and hypoxia markers of lactic acid (LA) and alanine (AL), and structural chemicals of proteoglycan (PG) and collagen or carbohydrate (CA).

An MR Spectroscopy (MRS) system and approach is provided for measuring spectral information corresponding with propionic acid (PA), either alone or in combination with other measurements corresponding with other chemicals, to diagnose and/or monitor at least one of bacterial infection, such as associated with P. acnes, or conditions related thereto such as nociceptive pain associated with tissue acidity. An interfacing DDD-MRS signal processor receives output signals to produce a post-processed spectrum, with spectral regions corresponding with certain chemicals, including PA, then measured as biomarkers. A diagnostic processor derives a diagnostic value for each disc, and performs certain normalizations, based upon ratios of the spectral regions related to chemicals implicated in degenerative painful tissue pathology, such as PA and hypoxia markers of lactic acid (LA) and alanine (AL), and structural chemicals of proteoglycan (PG) and collagen or carbohydrate (CA).

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., μmol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.

The present invention generally pertains to methods of characterizing antibody higher order structure. In particular, the present invention pertains to the use of novel NMR methods to compare manufacturing process variability in antibody higher order structure.